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1. Introduction  
Obesity-induced chronic systemic inflammation has been considered as a major risk factor 
for the development of type 2 diabetes mellitus (T2DM). In addition, the development of 
inflammation in adipose tissue has been speculated to be the main resource to initialize 
systemic inflammation and insulin resistance in the state of obesity. However, the molecular 
mechanisms underlying the development of adipose tissue inflammation are not yet 
completely characterized, which will be of clinical importance to clarify the potential drug 
targets for the prevention and treatment of obesity-associated T2DM. Thereby, the aim of 
this chapter will focus on reviewing the recent progress and prospective related to the 
understanding of obesity-induced adipose tissue inflammation and insulin resistance. The 
content of this chapter will highlight the possible contributing factors and interplay during 
the different developmental stages of obesity and associated insulin resistance. Accordingly, 
the possible roles of adipocytes, T cells, macrophages and endothelial cells in the initiation, 
propagation and exacerbation of adipose tissue inflammation will be further discussed. The 
cross-talk between cell types in the pathogenesis of inflamed adipose tissue and adipokine 
overproduction will also be extensively debated. Moreover, the important molecular 
mediators and/or chemokine and cytokine receptors in the development of obesity-induced 
adipose tissue inflammation and associated insulin resistance would also be added in the 
text. Finally, based on the recent advances in the relevant research field, the therapeutic 
strategies in the treatment of obesity-associated insulin resistance and T2DM will be 
discussed in this chapter.  
2. Obesity, adipose tissue inflammation and insulin resistance 
Obesity has reached epidemic proportions in most of the industrialized countries, resulting 
in an increasing prevalence of the metabolic syndrome characterized by visceral obesity, 
dyslipidemia, and insulin resistance. Obese adipocytes characterize as the important source 
of inflammation mediators by producing a large number of inflammatory cytokines and 
chemokines, such as TNF-alpha, IL-6, monocyte chemoattractant protein-1 (MCP-1), and 
dysregulated production of anti-inflammatory adipokines (e.g. adiponectin). Indeed, 
obesity-induced adipose tissue inflammation is the key process underlying activation of 
proinflammatory pathways known to interfere insulin signalling and induce insulin 
resistance. On the other hand, activation of inflammatory pathways in adipocytes impairs 
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triglyceride storage and increases release of free fatty acids (FFAs), an excess of which 
known to induce insulin resistance in muscle and liver (Guilherme & Virbasius, 2008).  In 
addition, it has been demonstrated that increased expression of MCP-1 in adipose tissue 
associated with obesity plays an important role in the pathogenesis of adipose macrophage 
infiltration and insulin resistance (Kanda, 2006). The infiltrated macrophages secrete a 
variety of chemokines and other cytokines that further promote a local inflammatory 
response resulting in subsequent systemic insulin resistance.  
3. Immune system and obesity-induced adipose tissue inflammation 
3.1 Innate immune system and the development of inflammation in adipose tissue 
Macrophages are the fundamental part of the immediate innate defense mechanisms, 
which can promote specific adaptive immunity by inducing T-cell recruitment and 
activation while the body is disturbed. Macrophages have attracted considerable recent 
attention in adipose tissue biology following the discovery that they infiltrate the tissue in 
obesity and appear to play a substantial role in the inflammatory process (Haiyan, 2003; 
Weisberg, 2003). The majority of macrophages in obese adipose tissue aggregate in 
“crown- like structure” completely surrounding dead (necrotic-like) adipocytes and 
scavenging adipocyte debris (Cinti et al. 2005). The number of macrophages positively 
correlates with body mass and adipocyte size in both subcutaneous and visceral fat 
depots, even though macrophage infiltration is more prominent in the latter. 
Accumulated macrophages are considered to be the critical link between obesity and 
adipose tissue inflammation since they are the major source of pro- inflammatory 
cytokine production, notably TNF-alpha and IL-6, in adipose tissue (Cancello, 2005; 
Haiyan, 2003). Interestingly, the process appears reversible since macrophage infiltration 
and pro-inflammatory marker expression in the adipose tissue of obese subjects can be 
significantly reduced after weight loss (Brun, 2006; Cancello, 2005). Similarly to any 
immune and inflammatory responses, macrophage infiltration in expanding adipose 
tissue results from blood monocytes influx, likely attracted by the chemokine MCP-1 
(Kanda, 2006). Indeed, it has been reported that MCP-1 secretion is markedly enhanced 
locally and in plasma in obese rodents and human patients. Mice with targeted deletion in 
the genes for monocyte MCP-1 and its receptor CCR2 both could attenuate adipose tissue 
macrophages (ATMs) infiltration and decrease inflammation in fat. It would subsequently 
protect these mice from high fat diet-induced insulin resistance (Kanda, 2006; Weisberg, 
2006). Conversely, MCP-1 overexpressed mice have increased numbers of ATMs along 
with insulin resistance (Kamei et al., 2006). Moreover, some mechanistic insights to 
explain how macrophages are associated with inflammation in obesity, have emerged 
from the characterization of ATM activation state. Macrophage population and function 
have been revealed to be highly heterogeneous and dependent on the surrounding 
environment, which has led to their characterization and classification following the well-
known classification of T-cell activation state into Th1/Th2 sub-types (Gordon, 2007). 
Typically, macrophages can be distinguished between the M1 phenotype, identified as the 
pro- inflammatory or “classifically”- activated state, secreting various cytokines (e.g. TNF-
alpha, IL-6), and the M2 phenotype referred as to the anti- inflammatory or 
“alternatively”- activated state, which produces IL-10. Following a pulse dye labelling of 
ATMs to discriminate newly infiltrated ATMs from the resident ATMs, it has been shown 
that recruited ATMs during a diet- induced obesity exhibit an inflammatory M1 profile 
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compared to already settled ATMs (Lumeng et al., 2007). Moreover, the same research 
group has also demonstrated that ATMs from lean mice retain the typical gene expression 
pattern of the M2 activation state, while ATMs from obese mice are characterized by 
enhanced expression levels of TNF-alpha and NOS2, both markers of the M1 activated 
state. This study supports that diet-induced obesity either converts or promotes the 
replacement of initial M2- polarized ATMs by M1- polarized ATMs, thereby contributing 
to the development of insulin resistance (Lumeng, 2007). In conclusion, ATMs are the 
major source of pro- inflammatory mediators in obese adipose tissue and contribute both 
to the local and systemic metabolic alterations and the general inflammatory state. Their 
number and activation states are likely crucial in the onset of obesity-associated adipose 
tissue inflammation and in the development of insulin resistance. 
3.2 Adaptive immune system and the development of inflammation in adipose tissue 
Macrophages infiltrating into adipose tissue during obesity could be largely extended by 
providing convincing evidence for an early participation of various cells from the adaptive 
immune system in the development of obesity (Kintscher, 2008; Rocha, 2008; Wu, 2007). For 
instance, T cells are also actively regulated in adipose tissue and contribute to obesity- 
induced inflammation. Previous studies have shown that specific rearrangements in the T 
cell receptor (TCR) are selected in adipose tissue, suggesting that antigens in fat may 
communicate with adaptive immune system (Nishimura et al., 2009). Several studies have 
pointed out that dietary (Rocha, 2008; Wu, 2007) or genetic obesity (Rausch et al., 2007) is 
associated with T- cell infiltration including both CD4+ and CD8+ T cells. The assessment of 
immune cell composition at early stage of high fat diet-induced obesity suggests that T-cell 
entry in adipose tissue precedes monocyte attraction and, therefore, might represent one of 
the processes initiating adipose tissue inflammation (Kintscher et al., 2008). Indeed, both the 
secretion of the chemokine C-C motif chemokine ligand (CCL) 5/ Regulated on Activation, 
Normal T Cell Expressed and Secreted (RANTES) and the expression level of its receptor 
CCR5 are enhanced in adipose tissue of obese male mice (Wu et al., 2007). Moreover, 
RANTES neutralization reduces T- cell migration in vitro. RANTES expression is not only 
restricted to T- cells but is also detected in mature adipocytes, more prominently in presence 
of TNF- alpha (Wu et al., 2007). CD4+ T cells in adipose tissue can be classified into pro-
inflammatory Th1 polarized T cells secreting IFN- gamma and anti- inflammatory Th2 
polarized T cells secreting IL-4 and IL-13. In lean mice, Th1 and Th2 polarized T cells are 
higher in visceral than in subcutaneous adipose tissue with both T- cell type being present at 
approximately equal amounts (Winer et al., 2009). In addition, the role of the Th1- type 
cytokine IFN- gamma in adipose tissue inflammation has been explored (Rocha et al., 2008). 
IFN- gamma mRNA expression was up-regulated in mouse adipose tissue after high fat diet 
feeding. 3T3-L1 adipocytes incubated with IFN- gamma exhibited a marked enhancement of 
the expression levels of various cytokines and chemokines. Moreover, IFN- gamma 
deficiency partly prevented the diet-induced increases of both ATM number and pro- 
inflammatory marker expression (TNF- alpha and MCP-1) in adipose tissue. On the other 
hand, several studies have also observed an increase in adipose tissue CD8+ T cells in the 
course of obesity (Nishimura, 2009; Winer, 2009). The infiltration of CD8+ T cells precedes 
the recruitment of macrophages in the development of adipose tissue inflammation 
(Nishimura et al., 2009). Depletion of CD8+ T cells before inducing obesity in mice prevents 
M1 macrophage infiltration into adipose tissue without changing adiposity or the number of 
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M2 macrophages residing in fat. In obese mice with existing inflammation, an antibody-
mediated reduction of CD8+ T cells improved glucose tolerance and insulin sensitivity 
along with adipose tissue inflammation, providing evidence for a role of these CD8+ T cells 
not only in the initiation but also preservation of inflammation in adipose tissue. 
Furthermore, adoptive transfer of CD8+ T cells to CD8- deficient mice lead to increase 
adipose tissue inflammation. In summary, adipose tissue expansion is associated with 
changes in the number and various phenotype of lymphocytes. A pathological role of Th1 
polarized T cells and CD8+ T cells in adipose could be described in the state of obesity 
correlating with adipose tissue inflammation and subsequent insulin resistance.  
4. Adipokine dysregulation in obesity and insulin resistance 
4.1 Obesity-induced upregulation of potentially deleterious adipokines 
4.1.1 Leptin 
Leptin is almost exclusively expressed and produced by white adipose tissue. Plasma Leptin 
concentration and mRNA expression in adipose tissue are directly related to the severity of 
obesity. An increase of fat mass is associated with the elevation of leptin (Considine et al., 
1996). In animal models, expression of leptin is increased in conditions that are associated 
with release of pro- inflammatory cytokines such as TNF- alpha and IL-6 in monocytes and 
macrophages. Vice versa, TNF- alpha and IL-6 are capable of stimulating adipocyte leptin 
production (Antuna-Puente et al., 2008). Leptin also has significant effect on adaptive 
immunity, such as inducing a switch toward Th1-cell immune responses by increasing IFN- 
gamma, TNF- alpha secretion, and the suppression of Th2- cell responses in adipose tissue 
(Matareseet al., 2002). On the other hand, leptin has also been reported to improve insulin 
sensitivity through activation of AMP-activated protein kinase (AMPK) (Minokoshi et al., 
2002). However, in human obesity, the high circulating leptin levels is exhibited secondary 
to the development of  leptin resistance. Leptin administration has little or no effect on 
insulin resistance. Moreover, the leptin-signaling pathway as shown to, activate suppressor 
of cytokine signaling (SOCS)-3, which might opposite effect to inhibit insulin signaling 
(Howard & Flier, 2006). Taken together, it is suggested that leptin has proinflammatory 
effects and is involved in the pathogenesis of insulin resistance. However, the underlying 
mechanism of leptin in the etiology of obesity- associated adipose tissue inflammation and 
insulin resistance needs to be further elucidated. 
4.1.2 Resistin 
Resistin received its name from the original observation that it induced insulin resistance in 
mice (Steppan et al., 2001). Resistin expression has demonstrated to be increased in obese 
animals and has been implicated in the pathogenesis of obesity- associated insulin resistance 
and type 2 diabetes mellitus in mouse model (Steppan et al., 2001). Accordingly, 
administration of recombinant resistin to normal animal produced insulin resistance, 
whereas neutralizing resistin with specific antibody improved insulin sensitivity in obese 
animals with insulin resistance. This work was the first to illustrate resistin as a link 
between obesity and insulin resistance (Kim et al., 2001). On the other hand, studies indicate 
that stimulation of macrophages in vitro with endotoxin or proinflammatory cytokines leads 
to a marked increase in resistin production. Furthermore, administration of endotoxin to 
human volunteers is associated with an dramatical increase in circulating resistin levels 
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(Lehrke et al., 2004). Previous report regarded to the effects of resistin in the modulation of 
inflammatory responses has shown that resistin could upregulate expression of MCP-1 as 
well as cell adhesion molecule ICAM-1 in endothelial cell (Kawanami et al., 2004). However, 
subsequent human studies failed to link resistin to insulin resistance. In addition, this 
protein is not produced by human adipocytes. Further investigation is needed to 
characterize the role of resistin in the pathogenic link between obesity-induced adipose 
tissue inflammation and insulin resistance in human. 
4.1.3 Visfatin 
Visfatin has recently been identified as an adipokine that is secreted by adipocytes in 
visceral fat, decreases insulin resistance (Fukuhara et al., 2005). In both genetic and 
nutritional obese animal models, visfatin expression is induced predominantly in visceral 
adipose tissue. Similarly to insulin, visfatin could enhance glucose uptake in myocytes and 
adipocytes, and also inhibit hepatocyte glucose production (Fukuhara et al., 2005). Its 
insulin- like effects are also reported that visfatin could induce tyrosine phosphorylation of 
insulin receptors insulin receptor substrate-1 and 2 (IRS-1, IRS-2), and activation of PI3K. 
The pro-inflammatory effect of visfatin has been demonstrated in unstable lesions in 
patients with coronary heart disease. It showed that visfain can increase matrix 
metalloproteinase-9 activity in monocytes, and TNF- alpha and IL-8 in peripheral blood 
mononuclear cells (Dahl et al., 2007). All these studies strongly suggest that visfatin could be 
primarily regarded as an inflammatory mediator involved in several obesity-related 
pathological processes. Nevertheless, the molecule of visfatin has turned out to be 
previously identified as a growth factor for early B-lymphocytes termed pre-B cell colony 
enhancing factor(PBEF) (Samal et al., 1994). The role of visfatin in human T2DM remains 
debated (Chen, 2006; Sandeep, 2007). 
4.1.4 TNF-alpha  
TNF-alpha is a proinflammatory cytokine produced by numerous cells, but mainly by 
macrophages, lymphocytes and monocytes. In addition, adipocytes also produce TNF-alpha 
in humans and rodents. TNF-alpha is the first inflammatory cytokine shown to be produced 
by adipocytes (Hotamisligil et al., 1993). TNF-alpha level is increased in adipose tissue and 
plasma of obese patients and has been related to obesity- associated complications (Kern et 
al., 2001). TNF-alpha has been considered to be crucially involved in the pathophysiology of 
insulin resistance (Hotamisligil et al., 1993). Disruption of IRS-1 phosphorylation by TNFǂ 
has been reported to one of the possible mechanisms to interfere insulin signaling. 
Moreover, TNF-alpha has been shown to inhibit the conversion of pre-adipocytes to mature 
adipocytes, allowing further recruitment of uncommitted cells and thus possible expansion 
of adipose tissue mass (Kras et al., 2000). Therefore TNF-alpha is considered a likely 
mediator of the insulin resistance and T2DM associated with high visceral adiposity.  
4.1.5 IL-6 
Like TNF-alpha, the levels of IL-6 positively correlates with body mass index, especially in 
the state of obesity (Kern et al., 2001). It has been estimated that white adipose tissue 
contributes about 30% of circulating IL-6. Visceral white adipose tissue (WAT) produces. 
Higher levels of IL-6 compared with those in subcutaneous WAT (Fain, 2004; Fried, 1998). 
Most of the IL-6 comes from the stromal vascular fraction of adipose tissue. There is a 
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positive relationship between IL-6 levels in adipose tissue and circulating C-reactive protein  
levels (Maachi et al., 2004), which is an important cardiovascular risk factor. Moreover, IL-6 
produced by intra-abdominal adipose tissue has been documented to directly link to 
visceral obesity- related hypertriglyceridaemia by stimulating hepatic secretion of 
triglycerides (Nonogaki et al., 1995). 
4.2 Obesity-induced downregulation of potentially beneficial adipokines 
4.2.1 Adiponectin 
Adiponectin is a protein highly expressed in adipose tissue. In contrast to other adipokines, 
adiponectin is underexpressed in obese patients with insulin resistance or T2DM. 
Adiponectin could enhance insulin sensitivity through activation of AMPK (Yamauchi et al., 
2002). In addition to its effects on insulin sensitivity, adiponectin has an anti-inflammatory 
effect through its anti- TNF-alpha action. For example, the in vitro study has demonstrated 
that macrophage activity and TNF-alpha production were significantly diminished in 
macrophages while cotreated with adiponectin (Ouchi et al., 2000). The anti-inflammatory 
activities of adiponectin extend to inhibition of IL-6 production accompanied by induction 
of the endogenous anti- inflammatory cytokines IL-10 and IL-1 receptor antagonist 
(Kumada et al., 2004). On the basis of all the above-mentioned studies, adiponectin appears 
to act as an anti- inflammatory molecule in adipose tissue. 
5. Cellular cross- talk and molecular mediators in the development of adipose 
tissue inflammation 
5.1 Adipocyte dysfunction and inflammation 
In obesity, excessive adipose tissue growth is associated with hypertrophy and hyperplasia 
of adipocytes. Excess energy intake or decreased expenditure results in excess TG 
accumulation and adipocyte hypertrophy in adipose tissue. Adipocyte size is related to 
dysregulated adipokines expression and secretion in humans. The hypertrophic adipocytes 
change their immune balance towards the production of pro- inflammatory, atherogenic 
and diabetic adipokines. Reportedly, the enlarged adipocytes appear to initiate 
macrophages infiltration which occurs secondarily in obesity through their dysregulated 
adipokine production (Jiao et al., 2009). Moreover, Nishimura et al showed that CD8+ T cells 
accumulated in obese adipose tissue, but not presence of greater number of CD8+ T cells in 
the systemic circulation in the state of obesity. The findings suggested that CD8+ T cells are 
activated by local stimulation in the adipose tissue (Nishimura et al., 2009). It implicates that 
obese adipose tissue activates CD8+ T cells via dysregulated adipokine expression. 
Adipocyte hypertrophy is associated with altered intracellular signaling. An increase in 
constitutive NF-κB activity has been reported in 3T3-L1 cell line during adipocyte 
differentiation and hypertrophy, which may potentially lead to adipokine overproduction 
(Berg et al., 2004). 3T3-L1 adipocyte hypertrophy could be artificially induced by preloading 
with palmitate, which in turn enhance oxidative stress and increase MCP-1 production 
through JNK and NF-κB signaling (Takahashi et al., 2008). In brief, adipose tissue might be 
regarded as an important source of inflammatory products in vivo (e.g. TNF-alpha, IL-6, 
leptin and adiponectin), which are regulated by the interactions among infiltrated immune 
cells and residual cells, i.e. adipocytes, endothelial cells in adipose tissue. Therefore, it could 
actively participate to initiate and regulate immune responses in local adipose tissue and 
whole body. 
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5.2 Hypoxia 
It has been speculated that the dysregulation of the production of inflammation-related 
adipokines in obesity, linked to the development of the metabolic syndrome and other 
obesity-associated disorders, is a specific response to relative hypoxia in clusters of 
adipocytes distant from the vasculature as adipose tissue mass expands. Hypoxia is 
exhibited in adipose tissue of obese individuals where oxygen partial pressure and blood 
flow are reduced. Moreover, the expression of hypoxia- inducible factor- 1 alpha (HIF-1 
alpha)-the master regulator of oxygen homeostasis” is higher in subcutaneous adipose 
tissue of obese vs. lean subjects (Cancello et al., 2005). In mouse model, hypoxia indicated by 
elevated HIF-1 alpha protein levels in WAT has also been demonstrated in both ob/ob mice 
and in diet- induced obese mice (Rausch, 2007; Ye, 2007). The presence of immunoreactive 
HIF-1 alpha, its induction by hypoxia and hypoxia mimetics have been demonstrated in 
several cell-based studies employing either the 3T3-F422A or 3T3-L1 adipocyte clonal cell 
lines (Chen, 2006; Lolmedet, 2003). Recent report has first showed that the production of 
angiogenic factors such as VEGF, leptin and matrix metalloproteinases are increased in 3T3-
F422A adipocytes in response to low O2 tension (5% O2) or chemical hypoxia. The 
downregulation of adiponectin gene expression by hypoxia in 3T3-L1 adipocytes has 
subsequently been confirmed (Hosogai et al., 2007), and occurs also in human adipocytes 
(Wang et al., 2007). The context of macrophage involved in adipose tissue function, with the 
induction of IL-6, MIF, TNF- alpha and VEGF gene expressions under hypoxia has been 
demonstrated in peritoneal macrophages (Ye et al., 2007). These observations suggest that 
there is a link between pockets of inflammation within WAT and the recruitment of 
macrophages into these same areas of the tissue through the hypoxia-mediated signaling 
and relevant adipokine production.  
5.3 Inflammatory fatty acids 
Obesity and insulin resistance are associated with high circulating concentrations of free 
fatty acids. A potential link between adipose tissue fatty acid composition and obesity has 
been high-lighted in several studies (Decsi, 1996; Williams, 2007). Arachidonate is the 
primary source of fatty acids that mediate inflammatory responses. In obese children from 
the Mediterranean region, arachidonate levels were increased in adipose tissue compared to 
those in lean children (Savvas et al., 2004). These findings link arachidonate levels in adipose 
tissue with obesity. Since arachidonate and fatty acid products in adipose tissue are 
important in regulating lipolysis, lipogenesis and adipogenesis, it is speculated that 
phospholipase A2 enzymes that release arachidonate from membrane phospholipids may 
be directly involved in these three processes. In fact, it has been demonstrated that knockout 
of the gene that encodes adipose-tissue specific phospholipase A2 enzyme (Group XVI 
phospholipase A2 or AdPLA) in mice increased the rate of lipolysis by markedly reducing 
prostaglandin E2 levels. These mice also showed reduced tissue mass, triglyceride levels, 
insulin resistance and increased fatty acid oxidation in obese adipocytes induced by either a 
high-fat feeding or leptin deficiency (Jaworski et al., 2009). Phospholipase A2 may also be 
important in releasing arachidonate from inflammatory cells to be later metabolized by 
other cells such as adipocytes. As a result, adipocytes may become chronically energy over- 
loaded, which may alter their secretory profiles. Secretory phospholipase such as secretory 
Phospholipase A2 from inflammatory cells could act to release arachidonate from 
neighboring cells including adipocytes. The cyclooxygenase 1 and cyclooxygenase 2 are 
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essential steps in the synthesis of prostanoids from arachidonate. Several studies have 
suggested that prostanoids modulate adipocyte differentiation and maturation (Shillabeer et 
al., 1998). The elevation in both prostaglandin E2 and prostaglandin I2 levels have been 
shown to induce adipocyte dysfunction (Kim & Moustaid-Moussa, 2000). Prostaglandin E2 
acts on EP3 receptors to decrease lipolysis by decreasing cAMP concentration and, thereby, 
contributes to the hypertrophic development of adipocyte (Jaworski et al., 2009). In addition, 
it has been demonstrated that cyclooxygenase (COX)-2 mediated inflammation in fat plays a 
pivotal role in the development of adipose tissue inflammation, insulin resistance and fatty 
liver in high fat- induced obese rats (Hsieh et al., 2009, 2010). The time- dependent increases 
in plasma insulin, glucose, leptin levels and homeostasis model assessment of insulin 
resistance (HOMA-IR) shown in high- fat induced obese rats were significantly reversed in 
those co-treated with a selective COX2 inhibitor (Celecoxib or Mesulid). COX2 inhibition 
also significantly reversed adipocyte hypertrophy, macrophage infiltration and decreased in 
markers of adipocyte differentiation shown in high fat diet- induced obese rats, especially in 
visceral fat rather than those in subcutaneous fat (Hsieh et al., 2009, 2010). In addition, in the 
COX2 deficient mouse model, PPAR-gamma (an adipocyte differentiation marker) mRNA 
expression in epididymal adipose tissue was reduced (Ghoshal et al., 2010). Recently, COX2 
has been shown to contribute to the differentiation of brown adipocytes in mice, following 
cold or adrenergic stimulation (Madsen, 2010 ; Vegiopoulos, 2010). They demonstrated that 
activating the COX2- mediated pathway in adipose tissue could trigger formation of lipid- 
burning brown adipose tissue and induce weight loss to treat obesity. But, the coming 
challenge is how to boost the pathway in adipose tissue without increasing COX2- related 
fat inflammation.  
6. Potential therapeutic drugs and immunotherapy in the treatment of obesity 
-induced adipose tissue inflammation and insulin resistance 
Various pharmacological interventions affect obesity-associated cardiometabolic 
abnormalities. The effects of these interventions depend on weight loss, changes in fat 
distribution and/or direct effects on adipose tissue inflammation. Furthermore, several 
pharmacological agents commonly used in patients with vascular diseases or diabetes mellitus 
also affect adipose tissue function by diverse mechanisms. Although the effects of these drugs 
on adipose tissue function are unintended, improving adipose tissue function of these 
treatments may causally link with their improving effects on vascular disease and T2DM. 
6.1 Salicylates and COX2 inhibitors 
Salicylates are one of the most commonly used nonsteroidal anti- inflammation drugs and 
have their main actions through COX inhibition. Selective COX2 inhibitors may improve 
obesity-associated adipose tissue abnormalities (Hsieh et al., 2009, 2010). Besides COX 
inhibiton, salicylates also act through inhibition of the activity of inhibitor of nuclear factor 
kappa-B kinase subunit beta (IKK-ǃ) leading to a reduction in translocation of NF-kB to the 
nucleus, which action is crucially involved in the anti-diabetic effect of aspirin (Yin et al., 
1998; Yuan et al., 2001). Accordingly, salicylate in doses of 3 and 4.5 grams per day 
improved insulin resistance as measured by using a hyperinsulinemic euglycemic clamp. It 
also decreased free fatty acid and increased adiponectin levels by 35~45% in patients with 
type 2 diabetes (Goldfine et al., 2008). 
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6.2 Beta- blockers 
Several recent investigations have focused on the effects of the beta-blockers on adipose 
tissue dysfunction (Gress et al., 2000; Pollare et al., 1989). However, it still remains debated. 
For instance, a combined ǃ1 and ǃ2- adrenoceptor agonist is capable of downregulating 
adiponectin and upregulating TNF-alpha mRNA in murine adipocytes (Sharma et al., 2001). 
Conversely, some of the recent developed ǃ- blockers do have beneficial effects on insulin 
resistance and adipokines without changes in weight. Nebivolol (5 mg daily), which has ǃ2 
intrinsic sympaticomimetic action, increases plasma adiponectin levels in overweight 
patients with hypertension (Celik et al., 2006). Celipprolol (up to 400 mg daily), a combined 
ǃ1 antagonist and ǃ2 agonist reduces plasma leptin levels without a change in body weight 
in patients with dyslipidemia (Malminiemi, 2000). 
6.3 Aldosterone antagonists   
Adipose tissue is capable of producing an unidentified mineralcorticoid releasing factor that 
may stimulate aldosterone production (Lamounier-Zepter & Ehrhart-Bornstein, 2006). In 
obese diabetic mice, blocking the mineralcorticoid receptor reduced the expression of pro- 
inflammatory cytokines in adipose tissue while it lead to an increased expression of 
adiponectin in cardiac and adipose tissue (Guo et al., 2008). Additional evidence for an 
important role of the mineralcorticoid receptor in adipose tissue comes from a study in 
obese mice. It showed that blocking the mineralcorticoid receptor with eplerone ameliorated 
insulin resistance, decreased the number of hypertrophic adipocytes and infiltrating 
macrophages (Hirata et al., 2009). 
6.4 Angiotensin converting enzyme inhibitors (ACEI) 
Angiotensin converting enzyme inhibitors (ACEI) could affect insulin resistance by 
reducing plasma concentration of angiotensin Ⅱ, which increases serine phosphorylation of 
the insulin receptor, insulin receptor substrate 1 and phosphadidylinositol-3-kinase leading 
to a state of insulin resistance (Folli et al., 1997). Angiotensin Ⅱ might also influence insulin 
resistance via a direct pro- inflammatory effect on adipocyte and subsequently change in 
MCP-1, IL-6 and IL-8 production via the NF-kB pathway and increase production of leptin 
via an ERK1/2 dependent pathway in a murine model (Skurk et al., 2004; Tsuchiya et al., 
2006). 
6.5 Statins 
Statins might alleviate adipose tissue inflammation by inhibiting Toll- like receptor-4 
triggered IFN-Ǆ expression in macrophages, which are abundant in adipose tissue and by 
increasing PPAR-Ǆ expression (Abe et al., 2008; Desjardins et al., 2008). Murine 3T3-L1 
adipocytes incubated with blood samples from patients treated with parvastatin have been 
demonstrated to induce adiponectin production (Takagi et al., 2008). Moreover, atorvastatin, 
which is more lipophylic than pravasatin increases adiponectin levels in patients with 
coronary artery disease (CAD) or at high risk for CAD while having no effect on adiponectin 
in patients with diabetes (Ichida et al., 2006). Simvastatin, the most lipophylic statin, 
decreases adiponectin (Devaraj et al., 2007). These observations suggest that hydrophilic 
statins have more beneficial effect than those of  lipophylic statins on adipose tissue 
dysfunction. 
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6.6 Thiazolidinediones 
Thiazolidinediones (TZDs) such as pioglitazone and rosiglitazone have been suggested to be 
the potential drugs in preventing T2DM. Treatment with rosiglitazone for 3 years have been 
reported to lower the incidence of T2DM (Gerstein et al. 2006). TZDs may directly increase 
insulin sensitivity in the liver and adipose tissue where it is of critical importance for 
adipocyte differentiation. PPAR-Ǆ agonists are thought to promote the uptake and storage of 
free fatty acids in adipocytes and may therefore protect the liver and muscle from the 
attacks of excess free fatty acids and their toxic effects. Also, PPAR-Ǆ agonists such as 
pioglitazone have been shown to increase high molecular weight adiponectin and decrease 
TNF-ǂand RBP-4 levels in patients with T2DM (Aso et al., 2007). 
6.7 Metformin 
Apart from affecting glucose uptake in the liver and peripheral tissues, metformin has anti- 
inflammatory properties by inhibiting NF-kB and blocking the PI3K- Akt pathway in human 
vascular cells (Isoda et al., 2006). Recent study suggests that the effect of metformin on 
AMP-activated protein kinase (AMPK) dependent lipolysis in adipocytes may lead to lower 
plasma levels of fatty acids and improve adipose tissue function (Bourron et al., 2010). 
Moreover, metformin has been reported to reduce subcutaneous adipose tissue, total body 
fat percentage, BMI and waist circumference but not affect the amount of visceral adipose 
tissue in obese children and adolescents (Srinivasan et al., 2006). However, in a study with 
lean and obese patients with and without diabetes, metformin did not result in a reduction 
of BMI, nor did it affect plasma adiponectin levels after 4 months of treatment (Phillips et al., 
2003). Thererby, the clinical implication of metformin on treatment of obesity remains 
controversial. 
6.8 Immunotherapy 
Nishimura and colleagues have shown that CD8+ T cells play the important role in 
macrophage recruitment and adipose tissue inflammation. They found that large numbers 
of CD8+ T cells infiltrated into obese epididymal adipose tissue and preceded the 
accumulation of macrophages in fat tissue of high-fat induced obese mice. In addition, the 
immunological and genetic depletion of CD8+ T cells have been reported to lower 
macrophage infiltration, adipose tissue inflammation and ameliorate systemic insulin 
resistance (Nishimura et al., 2009). Besides, Winer and colleagues demonstrated that 
immunotherapy with CD4+ T cell transfer into lymphocyte-free obese mice reversed weight 
gain and insulin resistance. Short-term treatment with CD3-specific antibody markedly 
reversed insulin resistance for months, despite continuation of a high-fat diet (Winer et al., 
2009). Taken together, these observations not only demonstrate the importance of immune 
response in the development of obesity, but also identify a number of novel targets and 
strategies that could be harnessed to treat obesity in manners similar to the treatment of 
other immunological abnormalities. 
7. Conclusion  
Obesity-induced inflammation in adipose tissue has been considered as one of the main 
contributors to the development of insulin resistance and subsequent T2DM in the state of 
obesity. Both of the innate and adaptive immune systems have been documented to be 
crucially involved in the initiation and regulation of adipose tissue inflammation. In the 
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meantime, the adipokine dysregulation and hypoxia-mediated signaling during the 
development of adipocyte hypertrophy are also actively participate into the pathogenesis of 
adipose tissue inflammation. Recently, the role of inflammatory fatty acids such as 
arachidonate in the etiology of adipogenesis and lipogenesis has also been the subject of 
intensive investigation. Although the detail mechanisms remain incompletely understood, it 
could be a promising therapeutic target for prevention and treatment of obesity-induced 
insulin resistance and T2DM in the prospective future. Besides, several therapeutic drugs 
used in the patients with vescular diseases or diabetes and immunotherapy have also been 
shown to reduce the risk of developing insulin resistance and T2DM.  
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